Malignancy in neurofibromatosis type 1

Oncologist

Volumn 5, Issue 6, 2000, Pages 477-485

  Korf, B R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Central nervous system; Malignant peripheral nerve sheath tumors; Neurofibromatosis type 1

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; COMPLEMENTARY RNA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; VINCRISTINE;

ARTICLE; AUTOSOMAL INHERITANCE; BRAIN TUMOR; CARCINOGENESIS; CLINICAL TRIAL; CONSERVATIVE TREATMENT; HUMAN; LEUKEMIA; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; ONCOGENE RAS; OPTIC NERVE GLIOMA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0033674591     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-6-477     Document Type: Article

References (83)

1. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations
2. Identifcation and characterization of transcripts from the neurofibromatosis 1 region: The sequence and genomic structure of EVI2 and mapping of other transcripts
3. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
4. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients
5. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
6. The neurofibromatosis type 1 gene encodes a protein related to GAP
7. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
8. A functional assay for heterozygous mutations in the GTPase activating protein related domain of the neurofibromatosis type 1 gene
9. Neurofibromatosis
10. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2
11. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene
12. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain
13. Use of 'unidentified bright objects' on MRI for diagnosis of neurofibromatosis 1 in children
14. Penetrance and variability in neurofibromatosis: A genetic study of 60 families
15. Familial neurofibromatosis 1 microdeletions: Cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata
16. Deletion of the entire NF1 gene detected by FISH: Four deletion patients associated with severe manifestations
17. Malignancy in neurofibromatosis
18. Neurofibromatosis and childhood tumors
19. Von Recklinghausen neurofibromatosis. A clinical and population study in southeast Wales
20. Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1,728 patients
21. Long-term follow-up of von Recklinghausen neurofibromatosis survival and malignant neoplasms
22. Neurofibromatosis type 1 and childhood cancer
23. Neurofibromatosis and other disorders among children with CNS tumors and their families
24. Sarcomas of the peripheral nerves and somatic soft tissues associated with multiple neurofibromatosis (von Recklinghausen's disease)
25. Malignant peripheral nerve sheath tumors. A clinicopathological study of 120 cases
26. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases
27. Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958-1984
28. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis
29. Neurofibromatosis type I and malignancy: Review of 32 pediatric cases treated at a single institution
30. Detection of malignant change in neurofibromatosis (von Recklinghausen's disease) by gallium-67 scanning
31. Evaluation of (18)fluorodeoxyglucose positron emission tomography (18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1
32. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis
33. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene
34. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models
35. Von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata
36. Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study
37. Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1
38. Precocious puberty in children with neurofibromatosis type 1
39. Optic glioma of childhood. Natural history and rationale for conservative management
40. Follow-up of optic pathway gliomas in children with neurofibromatosis type 1
41. Optic gliomas in neurofibromatosis type 1 (NF-1). Presentation of 31 cases
42. Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results
43. Spontaneous involution of optic pathway lesions in neurofibromatosis type 1: Serial contrast MR evaluation
44. Optic gliomas in neurofibromatosis type 1: Role of visual evoked potentials
45. Early diagnosis of optic glioma in children with neurofibromatosis type 1
46. Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force
47. Visual pathway glioma: An erratic tumour with therapeutic dilemmas
48. Optic pathway/hypothalamic gliomas: A dilemma in management
49. Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma
50. Optic glioma in children: Surveillance, resection, or irradiation
51. Moyamoya pattern of vascular occlusion after radiotherapy for glioma of the optic chasm
52. Moyamoya phenomenon after radiation for optic glioma
53. Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type-1
54. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: An update
55. Gliomas in neurofibromatosis: A series of 89 cases with evidence for enhanced malignancy in associated cerebellar astrocytomas
56. Favorable prognosis for brain stem gliomas in neurofibromatosis
57. The management of brain stem gliomas in patients with neurofibromatosis
58. Brainstem tumors in patients with neurofibromatosis type 1: A distinct clinical entity
59. Neurofibromatosis and childhood leukemia
60. Neurofibromatosis and childhood leukaemia/lymphoma: A population-based UKCCSG study
61. Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. World statistical analysis
62. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders
63. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras
64. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
65. Nf1 and Gmcsf interact in myeloid leukemogenesis
66. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines
67. Point mutations in human GLI3 cause Greig syndrome
68. The relationship between nephroblastoma and neurofibromatosis (von Recklinghausen's disease)
69. Synchronous neuroblastoma and von Recklinghausen's disease: A review of the literature
70. Childhood neurofibromatosis: Risk factors for malignant disease
71. Tumour predisposition in mice heterozygous for a targeted mutation in NF1
72. The neurofibromatosis type 1 messenger RNA undergoes base-modification RNA editing
73. Mouse tumor model for neurofibromatosis type 1
74. TP53 mutations are frequent in malignant NF1 tumors
75. Abnormal regulation of mammalian p21(ras) contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
76. Pregnancy after preimplantation genetic diagnosis for Charcot-Marie-Tooth disease type 1A
77. Farnesyltransferase inhibitors block the neurofibromatosis type 1 (NF1) malignant phenotype
78. NF1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: Reversion of some phenotypes by an inhibitor of farnesyl protein transferase
79. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
80. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
81. NF1 mRNA isoform expression in PC12 cells: Modulation by extrinsic factors
82. Inhibition of ras oncogene: A novel approach to antineoplastic therapy
83. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice